May ischemia modified albumin be a predictor in diagnosis of contrast induced nephropathy?

Basit Öğe Kaydı
dc.contributor.authorTopaloğlu, Ömercan
dc.contributor.authorDemir, Bilgin
dc.contributor.authorEkinci, Ferhat
dc.contributor.authorUzun, Mehmet
dc.contributor.authorKurtulmuş, Yusuf
dc.contributor.authorTurkon, Hakan
dc.contributor.authorDuman, Can
dc.date.accessioned2024-08-04T19:42:45Z
dc.date.available2024-08-04T19:42:45Z
dc.date.issued2018
dc.departmentİnönü Üniversitesien_US
dc.description.abstractAim: “Ischemia modified albumin” (IMA) was investigated as a possible biomarker in several diseases such as vascular disorders. We aimed to reveal the possible value of IMA in predicting the development of contrast induced nephropathy (CIN) after coronary angiography in patients with stable angina pectoris.Material and Methods: 106 patients underwent coronary angiography with a diagnosis of stable angina pectoris were included in our study. Basic demographic and clinical findings and laboratory values were recorded and analyzed. Serum creatinine (SCre) levels were also measured 48 hours after coronary angiography and recorded. Amount of contrast agent (CA) given during coronary angiography was recorded. The patients were divided into 2 groups: CIN positive and CIN negative groups.Results: CIN was developed in 14 patients (13%); and IMA levels were similar in CIN positive and negative groups (p>0.05). SCre (both measurements before and after CA administration) was not correlated with IMA levels. There was no association between drug usage and development of CIN (p>0.05). Comorbidities were not associated with the development of CIN (p>0.05) with the exception of hypertension (HT). Presence of hypertension (p=0.0393) and female gender (p=0.0199) was associated with development of CIN. Mean age was 61.3 and 52.3 in CIN positive and negative groups, respectively (p>0.05).Conclusion: Any specific biomarker indicating CIN is not available yet. Most frequently used marker is the measurement of SCre 24- 48 hours after administration of CA. We found IMA levels not to be a predictor for the development of CIN. Further investigations will clearly determine the importance of IMA as a biomarker in renal failure developed after CA administration.en_US
dc.identifier.doi10.5455/jtomc.2018.01.019
dc.identifier.endpage322en_US
dc.identifier.issn2636-7688
dc.identifier.issue3en_US
dc.identifier.startpage318en_US
dc.identifier.trdizinid285589en_US
dc.identifier.urihttps://doi.org/10.5455/jtomc.2018.01.019
dc.identifier.urihttps://search.trdizin.gov.tr/yayin/detay/285589
dc.identifier.urihttps://hdl.handle.net/11616/88657
dc.identifier.volume25en_US
dc.indekslendigikaynakTR-Dizinen_US
dc.language.isoenen_US
dc.relation.ispartofAnnals of Medical Researchen_US
dc.relation.publicationcategoryMakale - Ulusal Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.titleMay ischemia modified albumin be a predictor in diagnosis of contrast induced nephropathy?en_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

TR-Dizin İndeksli Yayınlar Koleksiyonu